Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial. - Wikidata - wikimedia - TriplyDB

Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial.

Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial.

http://www.wikidata.org/entity/Q47336480

about

Weight management in obesity - past and present LEADER 5: prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: baseline global data from the LEADER trial.Cardiovascular effects of phentermine and topiramate: a new drug combination for the treatment of obesity Association of body mass index with mortality and functional outcome after acute ischemic stroke.Off-label drugs for weight management.The importance of weight management in type 2 diabetes mellitus.The effectiveness of pharmaceutical interventions for obesity: weight loss with orlistat and sibutramine in a United Kingdom population-based cohort.Short-term effects of intragastric balloon in association with conservative therapy on weight loss: a meta-analysis.The effect of sibutramine prescribing in routine clinical practice on cardiovascular outcomes: a cohort study in the United Kingdom Interventions that cause weight loss and the impact on cardiovascular risk factors: a systematic review and meta-analysis.Weight loss is still an essential intervention in obesity and its complications: a review Aggressive clinical approach to obesity improves metabolic and clinical outcomes and can prevent bariatric surgery: a single center experience The prognostic importance of weight loss in coronary artery disease: a systematic review and meta-analysis.Paternal metabolic and cardiovascular risk factors for fetal growth restriction: a case-control study.Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association.Association of hypoglycemic treatment regimens with cardiovascular outcomes in overweight and obese subjects with type 2 diabetes: a substudy of the SCOUT trial Mortality rate and overweight: Overblown or underestimated? A commentary on a recent meta-analysis of the associations of BMI and mortality.Targets for body fat, blood pressure, lipids, and glucose-lowering interventions in healthy older people.Prestroke weight loss is associated with poststroke mortality among men in the Honolulu-Asia Aging Study.Pharmacotherapy for obesity: novel agents and paradigms.Why do we need drugs to treat the patient with obesity?A heart-adipose tissue connection in the regulation of energy metabolism.Factors influencing the decline in stroke mortality: a statement from the American Heart Association/American Stroke Association.Safety assessment of FDA-approved (orlistat and lorcaserin) anti-obesity medications.Evolution of pharmacological obesity treatments: focus on adverse side-effect profiles.Influence of sibutramine in addition to diet and exercise on the relationship between weight loss and blood glucose changes.Approaches to obesity management.Changes in body weight and blood pressure: paradoxical outcome events in overweight and obese subjects with cardiovascular disease.Rapid Surface Enhanced Raman Scattering (SERS) Detection of Sibutramine Hydrochloride in Pharmaceutical Capsules with a β-Cyclodextrin- Ag/Polyvivnyl Alcohol Hydrogel Substrate.An intragastric balloon produces large weight losses in the absence of a change in ghrelin or peptide YY.Obesity in primary care: prevention, management and the paradox.Relationship between HbA1c levels and risk of cardiovascular adverse outcomes and all-cause mortality in overweight and obese cardiovascular high-risk women and men with type 2 diabetes.A comparative study of five centrally acting drugs on the pharmacological treatment of obesity.An intragastric balloon in the treatment of obese individuals with metabolic syndrome: a randomized controlled study.2014 EASO Position Statement on the Use of Anti-Obesity Drugs.Examining the association between depression and obesity during a weight management programme.Gastrointestinal surgery for obesity and diabetes: weight loss and control of hyperglycemia.A randomized controlled trial to determine the efficacy of a high carbohydrate and high protein ready-to-eat food product for weight loss.Safety assessment of an anti-obesity drug (sibutramine): a retrospective cohort study.The benefits of weight loss, even if regained, in reducing cardiovascular disease: welcoming evidence!

P2860

Q26774747-F5FF9327-0225-475C-85BC-643F65E4FED9 Q31044140-9321E017-31F0-4F1F-96A2-4AEFB517A8B3 Q33572190-D4EBBCC1-E658-45C3-92B1-0439C46FEDB4 Q33747035-97020CF9-F458-4606-90C2-370D1AFB0160 Q33806796-B0EEC8C2-D1B3-4496-9FF7-DA0501B03ABA Q34547464-BF552A8F-CC7C-4511-871F-FD79AD8C5C3A Q35684845-875EDCB3-1ED0-4965-8A23-7546FADDD587 Q35896818-90843BD5-9E5A-4A3E-99BB-876C502ED3AB Q36001036-5CA550B6-F54D-48DB-A457-1FB0D54F31A8 Q36057310-02A848A2-AD90-4075-B2A5-378B354D42CC Q36090438-B28B1289-7E04-4A70-BDDF-DBCD0FBD1DE4 Q36291168-58A52319-82FB-453D-B1C5-EC5A5AABA54C Q36524299-C64E87C8-B118-40B1-9D23-0B8E10A48678 Q36868226-83ECDE0B-6DAA-4F14-8C98-22F6472A4F51 Q37251490-51C3CF0B-709D-4B57-9EE7-52A65FFECE46 Q37277912-26D29532-DF69-4FE9-8A2F-12572D0E31FB Q37279460-14FB65D2-2B79-41D8-9050-8553C11EE9C6 Q37577151-2988F83B-9F24-4E9F-93CA-4AED52841000 Q37619939-0A1AF4DC-E300-45C3-887D-957E109C839E Q37712227-0C71A23B-4822-4781-9D81-6A7A5C392089 Q38092069-EDBA1A78-3E85-4B86-9705-5B45B42939CD Q38168030-BA2EE834-C08A-4391-9345-E1142B13112E Q38169038-8F63C748-EF1A-4C2A-9D64-46E46D3D1B28 Q38308961-AA45BAC0-2E38-49B2-B823-05D0BDDF6EB3 Q38758765-C8CAA73B-B0E0-4D35-8A5C-403F98EB494C Q39118038-20A48810-9B79-46A2-83A6-7CC95C7A123B Q39414599-C6226E7E-4951-4D1D-B2B1-93943ABED473 Q39444444-2A87B62D-B751-417A-98AC-E3D8AB4C0A82 Q41205552-FB55F633-9AA6-4617-9265-C3DFAE129585 Q41585514-6AE00D44-654F-41F2-AEF0-2E3F025FEB09 Q43099548-FF5449DA-77D2-46AC-BFCB-878BB0871EE6 Q43729526-9E06E09F-0E41-422B-BECF-71B0E1561AEB Q46186166-A8D08D6B-403D-412A-AB34-56E4681FDBA8 Q46548666-6C149EB8-17EE-443F-B193-2EB78675EC99 Q47129264-2045CFF6-55D8-43F7-B567-37BAA196F342 Q47194653-BF534FF9-AAB3-4DD1-8A6C-2531F1171B22 Q47279738-449FA0B5-F584-41BC-8C38-C041002DD274 Q47332174-76AFC6E7-3ACB-451B-AFD8-01CF36B9E4F6 Q47392852-BF543DFD-5C5D-4915-BE2F-2F93E71F8576 Q47396917-05BCD2F3-6D77-4EF1-AE9E-F0A6A7DD1EE0

P2860

Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial.

http://www.wikidata.org/entity/Q47336480

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh-hant

name

Maintained intentional weight ...... scular OUTcomes (SCOUT) trial.

@en

Maintained intentional weight ...... ramine Cardiovascular OUTcomes

@nl

type

label

Maintained intentional weight ...... scular OUTcomes (SCOUT) trial.

@en

Maintained intentional weight ...... ramine Cardiovascular OUTcomes

@nl

prefLabel

Maintained intentional weight ...... scular OUTcomes (SCOUT) trial.

@en

Maintained intentional weight ...... ramine Cardiovascular OUTcomes

@nl

P1433

Q47336480-DEB5206A-6050-4176-93E2-53A480846CC5

P1476

Q47336480-1A75B0B0-7E4F-4A2F-ABF8-540BF132B948

P2093

Q47336480-005F5B0F-661D-447B-B160-09011D53481C

Q47336480-194CF2FF-1A73-49CA-9D13-9C356D905E91

Q47336480-19715BB6-60AD-4533-A779-6063CAC7DFD9

Q47336480-44A282EB-C519-42AD-BCFA-9C46D74A58DD

Q47336480-4A0D71CE-B56B-4777-B506-18591DF5B6AF

Q47336480-72D3CD03-3470-416B-9DFA-E07C3F8D041F

Q47336480-748BCBBE-F048-496E-82D0-9AAEC3C3029C

Q47336480-9B0238CC-D2DA-4B76-9A79-848A2A6B88D6

Q47336480-B328D692-CB84-4AA6-AF23-A3237A2089B0

Q47336480-B78B4D03-6135-47C2-86E1-6ED2FABD7DC0

P2860

Q47336480-01ADFD60-2EFB-4BBC-98CD-FBD88ECF1C93

Q47336480-2962FE65-D8B2-441E-8A67-DDF75F10BA72

Q47336480-2AA9BB82-23D2-40EF-9773-94CFECA9EB28

Q47336480-30B83B7D-5543-43BD-8865-E14AA100DADE

Q47336480-346FECCA-CDAA-431C-BAFA-D6EE2B14E800

Q47336480-39B3AAD4-5147-4E78-87C8-BA43CEB8C42E

Q47336480-4D0693B4-DF62-4109-BBD5-AFA950910CFF

Q47336480-55763DD3-5546-4344-B459-EB309176A2A8

Q47336480-58FF2100-AABB-45D5-82B3-C3E3ACE97427

Q47336480-685710D0-28FB-40A8-96CD-F8F1C7DD132B

P304

Q47336480-4A306521-D5BF-49D5-BD5A-616CDCA544A4

P31

Q47336480-87892DA5-2AEC-4638-861D-CD7AB6E188E7

P356

Q47336480-E3E12ED2-1DDE-4810-A3ED-827BCA9C6E1F

P433

Q47336480-122E4F31-2120-45E1-9C0D-D52185B117DD

P478

Q47336480-CD16B5A4-0356-4FEB-9F21-913584264428

P50

Q47336480-0B48367B-1F57-4F1C-8986-735C3F1AC509

Q47336480-48F84A1F-9A0A-4DFD-947D-DC05B24F9FD3

Q47336480-C38A8321-5EE5-4D6E-98E5-AE267BDD2B76

P577

Q47336480-BEC8B494-3EA7-4085-8EB6-DE21A78B36B3

P5875

Q47336480-866CC36A-B81E-4D53-A687-B39CB2C0EC74

P698

Q47336480-EF9B0378-EFD0-4E2D-BA6F-548A87150634

P921

Q47336480-DAECABAF-CD2D-45F4-95F6-476930FFD75C

P356

J.1463-1326.2011.01554.X

P1433

Diabetes, Obesity and Metabolism

P1476

Maintained intentional weight ...... scular OUTcomes (SCOUT) trial.

@en

P2093

A M Sharma

http://www.w3.org/2001/XMLSchema#string

C L Renz

http://www.w3.org/2001/XMLSchema#string

G M Shepherd

http://www.w3.org/2001/XMLSchema#string

I D Caterson

http://www.w3.org/2001/XMLSchema#string

L F Van Gaal

http://www.w3.org/2001/XMLSchema#string

R A Rode

http://www.w3.org/2001/XMLSchema#string

R J Perdok

http://www.w3.org/2001/XMLSchema#string

SCOUT Investigators

http://www.w3.org/2001/XMLSchema#string

U F Legler

http://www.w3.org/2001/XMLSchema#string

W Coutinho

http://www.w3.org/2001/XMLSchema#string

P2860

Effects of Bariatric Surgery on Mortality in Swedish Obese Subjects

10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study

Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies

Long-term mortality after gastric bypass surgery

10-year follow-up of intensive glucose control in type 2 diabetes

Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects.

Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study.

Mechanisms linking obesity with cardiovascular disease.

Effects of intended weight loss on morbidity and mortality: possible explanations of controversial results.

Long-term effects of change in body weight on all-cause mortality. A review.

P304

523-530

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1463-1326.2011.01554.X

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P50

Christian Torp-Pedersen

Aldo P Maggioni

P577

2012-01-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51908705

http://www.w3.org/2001/XMLSchema#string

P698

22192338

http://www.w3.org/2001/XMLSchema#string

P921

Aparato circulatorio